The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.

Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel JF. Cancer. 2016 May 18. doi: 10.1002/cncr.30026. [Epub ahead of print] PMID: 27191689 [PubMed - as supplied by publisher] READ MORE

Posted: May 26, 2016

CHAMPION-1: a phase 1/2 study of weekly carfilzomib and dexamethasone for relapsed or relapsed and refractory multiple myeloma.

Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, Agajanian R, Boccia R, Coleman M, Moss RA, Rifkin RM, Patel P, Dixon S, Ou Y, Anderl J, Aggarwal S, Berdeja JG. Blood. 2016 May 12. pii: blood-2015-11-683854. [Epub ahead of print] PMID: 27207788 [PubMed - as supplied by publisher] READ MORE

Posted: May 26, 2016

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H. Blood. 2016 May 23. pii: blood-2016-03-705210. [Epub ahead of print] PMID: 27216216 [PubMed - as supplied by publisher] READ MORE

Posted: May 26, 2016

Page 27 of 87« First...1020...2526272829...405060...Last »